ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,922.01
0.08%
US Tech 100
20,083.20
-0.22%
다우존스 지수
43,535.46
0.29%
Bitcoin
97,461.16
3.29%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Atossa Therapeutics Inc (ATOS) 시세

Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

NASDAQ
1.175
-0.025
( -2.08% )
업데이트: 23:37:37
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
1.175
매수가
1.17
매도가
1.18
거래량
93,886
1.17 일간 변동폭 1.20
0.70 52주 범위 2.31
market_cap
147.816M
전일 종가
1.20
개장가
1.19
최근 거래 시간
200
@
1.175
마지막 거래 시간
23:37:37
재정 규모
US$ 111,630
VWAP
1.189
평균 볼륨(3m)
584,439
발행 주식
125,801,254
배당수익률
-
주가수익률
-5.02
주당순이익(EPS)
-0.24
매출
-
순이익
-30.09M

Atossa Therapeutics Inc 정보

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.atossatherapeutics.com
본부
Wilmington, Delaware, USA
설립됨
-
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ATOS. The last closing price for Atossa Therapeutics was US$1.20. Over the last year, Atossa Therapeutics shares have traded in a share price range of US$ 0.70 to US$ 2.31.

Atossa Therapeutics currently has 125,801,254 shares in issue. The market capitalisation of Atossa Therapeutics is US$150.96 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -5.02.

ATOS 최신 뉴스

추가 뉴스

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of...

1 시간 전
GlobeNewswire Inc.

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

20 11월 2024
GlobeNewswire Inc.

Form 8-K - Current report

20 11월 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

20 11월 2024
Edgar (US Regulatory)

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key...

12 11월 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

09 11월 2024
Edgar (US Regulatory)

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice...

05 11월 2024
GlobeNewswire Inc.

Form 8-K - Current report

04 11월 2024
Edgar (US Regulatory)

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa...

04 11월 2024
GlobeNewswire Inc.

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was well tolerated and...

31 10월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.215-15.46762589931.391.411.1710149641.27767719CS
4-0.275-18.96551724141.451.661.177341461.39705271CS
12-0.245-17.25352112681.421.661.175844391.42167796CS
26-0.415-26.10062893081.591.711.027108291.33733856CS
520.43558.78378378380.742.310.79406971.43119896CS
156-1.175-502.352.450.510206021.29467965CS
260-0.095-7.480314960631.279.80.535420193.16527336CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
WORXSCWorx Corporation
US$ 1.95
(98.98%)
36.13M
SPAISafe Pro Group Inc
US$ 5.56
(73.75%)
25.83M
SKKSKK Holdings Limited
US$ 7.56
(65.79%)
157.62k
CDTConduit Pharmaceuticals Inc
US$ 0.127
(37.59%)
232.52M
CRNCCerence Inc
US$ 3.8219
(35.53%)
1.43M
PYXSPyxis Oncology Inc
US$ 2.0299
(-46.86%)
3.39M
KURAKura Oncology Inc
US$ 11.56
(-27.34%)
1.02M
BLRXBioLineRx Ltd
US$ 0.4038
(-25.94%)
2.82M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 3.66
(-23.43%)
8.72M
AGFYAgrify Corporation
US$ 30.075
(-22.41%)
141.46k
CDTConduit Pharmaceuticals Inc
US$ 0.127
(37.59%)
232.52M
AKTSAkoustis Technologies Inc
US$ 0.0957
(9.87%)
140.31M
NVDANVIDIA Corporation
US$ 148.255
(1.62%)
60.53M
WORXSCWorx Corporation
US$ 1.95
(98.98%)
36.13M
PETWag Group Company
US$ 0.245
(16.61%)
32.71M

ATOS Discussion

게시물 보기
XenaLives XenaLives 3 월 전
Why on earth did it take me so long to find this?



Following...

https://x.com/stevenquay
👍️0
XenaLives XenaLives 3 월 전
I think I'm in love... LOL!!!



Historical perspective:

👍️0
XenaLives XenaLives 3 월 전
More interesting...

https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 3 월 전
ATOS chart...

👍️0
XenaLives XenaLives 3 월 전
Interesting .. also from Google...

A response to this query...

what is unique about atossa therapeutics inc

Response...

Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39

ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ

WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?


👍️0
XenaLives XenaLives 3 월 전
From Google Generative AI:


Atossa Therapeutics is a clinical-stage biopharmaceutical company that develops innovative medicines for oncology, with a focus on breast cancer and other breast conditions. Some unique aspects of Atossa Therapeutics include:
Patented (Z)-endoxifen
Atossa has patented the chemical process and composition of matter for (Z)-endoxifen, as well as a patented oral enteric capsule formulation.
Phase 2 I-SPY 2 Clinical Trial
Atossa is fully enrolling this trial, which is evaluating (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive breast cancer.
Phase 2 trials
Atossa is currently studying (Z)-endoxifen in four Phase 2 trials, including one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies.
U.S. patents
Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications.
👍️0
XenaLives XenaLives 3 월 전
Intriguing science...
👍️0
XenaLives XenaLives 3 월 전

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-00701&r=1
👍️0
XenaLives XenaLives 3 월 전
Link to Atossa pipeline...
https://atossatherapeutics.com/product-pipeline/
👍️0
XenaLives XenaLives 3 월 전
Following - some valid science is going on here...
👍️0
glenn1919 glenn1919 3 월 전
ATOS....................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 월 전
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 월 전
ATOS...............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️ 1
Joeyohso Joeyohso 7 월 전
Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem
👍️0
ShadowDiviner72 ShadowDiviner72 7 월 전
New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE
👍️0
glenn1919 glenn1919 8 월 전
ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Joeyohso Joeyohso 8 월 전
Why the dump today? I was able to grab some at 1.65
👍️0
Monksdream Monksdream 8 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 8 월 전
ATOS new 52 hi
👍️0
Monksdream Monksdream 8 월 전
ATOS 10Q due 4/5
👍️0
Monksdream Monksdream 8 월 전
ATOS new 52 hi
👍️0
glenn1919 glenn1919 8 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
ATOS..LEVEL 2 LOOKING VERY NICE IN PRE
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73
👍️0
glenn1919 glenn1919 8 월 전
ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 월 전
ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 월 전
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 년 전
ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Birdbrain Ideas Birdbrain Ideas 1 년 전
There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.
👍️0
Laster Laster 1 년 전
I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.
👍️0
tw0122 tw0122 1 년 전
Looking good. Hidden gem not any longer
👍️0
killrEngineer killrEngineer 1 년 전
Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.
👍️0
DrJinx DrJinx 2 년 전
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
👍️0
Engle1488 Engle1488 2 년 전
We are primed for a big run up people. In at 1.04
👍️0
Agreed Agreed 2 년 전
The market cap is less than their holdings in cash...clearly undervalued.
👍️0
Agreed Agreed 3 년 전
Insider buying by CEO and CFO, new patent protections...looking promising.
👍️0
DollarSquad DollarSquad 3 년 전
Yes. You likely lost a lot of money. This investment is worthless. RMSL
👍️0
4MVault 4MVault 3 년 전
Did something just happen?
👍️0
slugo1 slugo1 3 년 전
Looking for bottom here
👍️0
ttottip ttottip 3 년 전
Yes, very soon. This will reverse the trend.
👍️0
slugo1 slugo1 3 년 전
Soon
👍️0
ttottip ttottip 3 년 전
Soon the 2.5's , 2.6's .....
👍️0
slugo1 slugo1 3 년 전
Yes
👍️0
ttottip ttottip 3 년 전
The 2.6's on the horizon.
👍️0
slugo1 slugo1 3 년 전
That's one of the things I like about them Also there should be some updates coming
👍️0
ttottip ttottip 3 년 전
140 millions of dollars cash? ATOS can do great things with this money.
👍️0
slugo1 slugo1 3 년 전
Nice buy worth alot when this hits $10.00
👍️0
ttottip ttottip 3 년 전
Almost 36,000 shares buy at 2.49.
👍️0
DrHarleyboy DrHarleyboy 3 년 전
Good Old "Blue Sky Breakout"././//./..//.///.././..////
👍️0

최근 히스토리

NASDAQ
ATOS
Atossa Therapeutics
LSE
RIO
Rio Tinto
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유